Clinical trials: Community Pneumonia
Community Acquired Pneumonia
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
The purpose of this study is to determine whether the adjunctive therapy to standard antibiotic treatment of BT086 is safe and effective of decreasing the days patients require endotracheal ventilation due to Severe…
- Trial name
- CIGMA (NCT01420744)
- Testing
- BT086, 1% Human Albumin infusion
- Where
- 36 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Biotest
Community-acquired Pneumonia
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of Eucalyptol, Limonene and Pinene Enteric Soft Capsules in the treatment of community-acquired pneumonia can be made.
- Trial name
- NCT05002192
- Testing
- Eucalyptol, Limonene and Pinene Enteric Soft Capsule, Ambroxol injection, Other oral mucolytic drugs
- Where
- 7 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Grand Johamu Pharmaceutical Company, Ltd.
Community-Acquired Pneumonia
Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia
This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia(CAP)
- Trial name
- NCT00434291
- Testing
- TG-873870(Nemonoxacin)
- Where
- 20 sites in South Africa, Taiwan
- Volunteers
- 264 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336505
- Testing
- Cethromycin, Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 584 people
- Sponsor
- Advanced Life Sciences, Inc.
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336544
- Testing
- Cethromycin, Clarithromycin
- Where
- 13 sites in United States
- Volunteers
- 522 people
- Sponsor
- Advanced Life Sciences, Inc.
Community-acquired Pneumonia, Pneumonia
Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
- Trial name
- NCT06263881
- Testing
- Raphamin
- Where
- 38 sites in Russia
- Volunteers
- 370 people
- Sponsor
- Materia Medica Holding
Covid19
Feasibility of Remote Evaluation and Monitoring of Acoustic Pathophysiological Signals With External Sensor Technology in Covid-19
The aim of this study is to explore the acceptability and feasibility of a novel medical device system for autonomously monitoring of breath and heart sounds in Covid-19 (detecting and monitoring the progression of Covid-19…
- Trial name
- REMAP-WEST-COV (NCT04695821)
- Testing
- Senti V1.0 Device
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Senti Tech Ltd
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
Community Acquired Pneumonia (CAP), Complicated Skin and Skin Structures Infections (cSSSI)
Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections
This study will collect real-life data from patients with community acquired pneumonia (CAP) OR complicated skin and skin structure infections (cSSSI) to assess the burden of the disease, review the treatment pathways, evaluate…
- Trial name
- REACH (NCT01293435)
- Where
- 163 sites in Belgium, France and 8 more
- Volunteers
- 4,035 people
- Sponsor
- AstraZeneca
Pneumonia
A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia
The purpose of this study is to evaluate the effectiveness and safety of two antibiotic regimens in the treatment of community-acquired pneumonia in non-hospitalized adult patients.
- Trial name
- NCT00236821
- Testing
- levofloxacin
- Volunteers
- 530 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonia
Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
The purpose of this study is to compare the clinical cure rate (ratio of clinically cured patients to the total number of patients) of ceftobiprole medocaril versus a comparator in the treatment of patients with…
- Trial name
- NCT00326287
- Testing
- Ceftobiprole medocaril, Ceftriaxone with or without Linezolid
- Volunteers
- 638 people
- Sponsor
- Basilea Pharmaceutica
Pneumonia
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
- Trial name
- NCT00084071
- Testing
- Tifacogin
- Where
- 150 sites in United States, Argentina and 16 more
- Volunteers
- 2,136 people
- Sponsor
- Novartis Pharmaceuticals
Vaccine Response Impaired, Vaccine Adverse Reaction
Vaccine Observation to Include All Communities for Equitable Science
VOICES is a longitudinal, prospective, observational study that will enroll up to 10,000 subjects of diverse racial backgrounds being administered an emergency use authorized COVID-19 vaccine, for collection and analysis of stool…
- Trial name
- VOICES (NCT04770649)
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
Community Acquired Pneumonia
Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia
A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
- Trial name
- NCT01081964
- Testing
- Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- IASO Pharma Inc.
Pneumonia, Community-Acquired
A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults
To evaluate the clinical efficacy and safety in patients with mild or moderate community-acquired pneumonia receiving a dose of 2 g of azithromycin in the SR formulation.
- Trial name
- NCT00360295
- Testing
- Azithromycin SR
- Where
- 54 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Pfizer
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Community Acquired Pneumonia
Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
- Trial name
- NCT00653172
- Testing
- NXL103, comparator
- Where
- 60 sites in Chile, Croatia and 7 more
- Volunteers
- 302 people
- Sponsor
- Novexel Inc
Community Acquired Pneumonia (CAP)
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.
- Trial name
- NCT04613375
- Testing
- Urine sample collection, Saliva collection
- Where
- 5 sites in Spain
- Volunteers
- 1,821 people
- Sponsor
- Pfizer
Community Acquired Pneumonia (CAP)
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community…
- Trial name
- NCT00809328
- Testing
- Azithromycin
- Where
- 34 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Pfizer